RAAV2tYF-GRK1-RPGR clinical trials
RAAV2tYF-GRK1-RPGR is named as an intervention in 2 current clinical trials in our USA register. None are recruiting at the moment. The most common phase is Phase 1/2. The lead sponsor is Beacon Therapeutics. The most-studied condition is X-Linked Retinitis Pigmentosa.
Patient leaflets for RAAV2tYF-GRK1-RPGR
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of RAAV2tYF-GRK1-RPGR
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)
NCT06333249 · X-Linked Retinitis Pigmentosa
|
Phase 2 | Active, closed | Beacon Therapeutics | USA |
|
Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations
NCT03316560 · X-Linked Retinitis Pigmentosa
|
Phase 1/2 | Active, closed | Beacon Therapeutics | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with RAAV2tYF-GRK1-RPGR
1 conditionSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Beacon Therapeutics | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about RAAV2tYF-GRK1-RPGR trials
How many clinical trials are testing RAAV2tYF-GRK1-RPGR?
2 current trials in our USA register name RAAV2tYF-GRK1-RPGR as a drug or biological intervention, as of the registry sync on 8 November 2026. Completed and withdrawn studies are not counted.
Are RAAV2tYF-GRK1-RPGR trials recruiting patients?
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Who sponsors RAAV2tYF-GRK1-RPGR clinical trials?
The lead sponsor is Beacon Therapeutics. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how RAAV2tYF-GRK1-RPGR works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RAAV2tYF-GRK1-RPGR works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RAAV2tYF-GRK1-RPGR (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 8 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.